University of Alabama at Birmingham
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).
University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.
University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,160 total, page 13 of 24
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
NCT03501979
Embolization in Splenic Trauma
NCT03613454
A Multi-level Approach to Violence Prevention Among African American Adolescents
NCT03615716
Acceptance-based Care for Child Eating and Physical Activity Treatment
NCT03368716
[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
NCT03648073
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU
NCT04354467
The Impact of Arts-Based Interventions on Patient Hospital Experience
NCT04024670
Implementing the Decision-Aid for Lupus (IDEAL Strategy)
NCT03735238
Enhancing Shared Decision-Making in Breast Cancer
NCT03806738
Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations
NCT03624101
Exercise and Learning and Memory in Multiple Sclerosis
NCT03319771
The Effects of a High Intensity Exercise Training Program in Patients With Parkinson's Disease
NCT02593955
Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort
NCT03682809
Preterm Induction of Labor Timing of Amniotomy: A Randomized Controlled Trial
NCT03504670
Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance
NCT03530631
Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
NCT03597620
Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence
NCT03538808
CPR Decision Aid For Patients With Advanced Gynecologic Malignancies
NCT03251976
Preadmission Skin Wipe Use for Surgical Site Infection Prophylaxis in Adult Orthopaedic Surgery Patients
NCT03401749
Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression
NCT03441282
Older Veterans EmpoweRed To Use Regular Exercise (OVERTURE) II
NCT03580551
An Upstream Palliative Care Intervention for Rural and African-American Advanced Cancer Family Caregivers
NCT03464188
Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid
NCT03430310
Music Therapy Versus Control for Total Knee Arthroplasty
NCT03569397
The Effect of White and Pink Noise on Hospitalized Older Adults
NCT03485183
Prevention Through Intervention: Telehealth Solution to Deter 911 Calls Due to Hypoglycemia
NCT03665870
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
NCT03572049
Progenitor Potential of Mesenchymal Stem Cells in Palatal Tissue Harvested From Molar and Premolar Sites
NCT03570333
Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
NCT03286556
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
NCT03567980
Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
NCT03166202
Effect of Increased Enteral Protein on Body Composition of Preterm Infants
NCT03586102
Mixed Reality Gaming for Chronic Low Back Pain
NCT03603028
Speed of Processing Training for Cognitive Deficits After Delirium in Older Adults
NCT03342989
Determination of the Independent Effects of Beetroot Juice Components, Dietary Nitrate and Antioxidants, on Exercise Tolerance and Health Benefits in Individuals With Obesity
NCT03545009
Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies
NCT03244059
Treating Contact Lens Discomfort With Orthokeratology
NCT03566680
Potato Consumption and Energy Balance
NCT03518515
A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases
NCT03412812
The Effect of Music in the Pediatric Emergency Department Waiting Room on Caregiver Anxiety
NCT03384576
Aversive Therapy for Smoking Cessation
NCT03450148
Glaucoma Management Optimism for African Americans Living With Glaucoma
NCT03159481
Effect of Time-Restricted Feeding on Fat Loss and Cardiometabolic Risk Factors in Overweight Adults
NCT03459703
Cesarean Section Via Enhanced Recovery
NCT03552822
Dextromethorphan in Fibromyalgia
NCT03538054
Virtual Reality Walking for Neuropathic Pain in Spinal Cord Injury
NCT03735017
Single-Use Negative Pressure Wound Therapy for Free Flap Donor Sites
NCT03340025
REduCing Immunogenicity to PegloticasE (RECIPE) Study
NCT03303989
Brain Stimulation and Rehabilitation for Adults With Chronic, Severe Arm Motor Impairment After Stroke
NCT03538795
Improving Child Restraint Installation
NCT03508843
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 129 |
| Phase 2 | 130 |
| Phase 3 | 25 |
| Phase 4 | 72 |
Therapeutic Areas
What is open in the University of Alabama at Birmingham pipeline
216 recruiting of 1,160 indexed (19% open); 723 completed (62%).
Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Alabama at Birmingham: open-pipeline peers nationwide
Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,160 trials (± recruiting share)
- NYU Langone Health · 1,164 trials · 17% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 19% open enrollment (± trial volume)
- University of Minnesota · 19% recruiting · 966 trials
- Mclean Hospital · 19% recruiting · 140 trials
- Children's Hospital Medical Center, Cincinnati · 19% recruiting · 571 trials
- Arkansas Children's Hospital Research Institute · 19% recruiting · 97 trials
Related
What to do with this University of Alabama at Birmingham page
1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.
- 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.